作者: Nicholas J Leeper , Anna Bauer-Mehren , Srinivasan V Iyer , Paea LePendu , Cliff Olson
DOI: 10.1371/JOURNAL.PONE.0063499
关键词:
摘要: Background Peripheral arterial disease (PAD) is a growing problem with few available therapies. Cilostazol the only FDA-approved medication class I indication for intermittent claudication, but carries black box warning due to concerns increased cardiovascular mortality. To assess validity of this warning, we employed novel text-analytics pipeline quantify adverse events associated use in clinical setting, including patients congestive heart failure (CHF).